Showing 7131-7140 of 7422 results for "".
- Women's Dermatologic Society Event January 15https://practicaldermatology.com/news/20130111-womens_dermatologic_society_event_january_15/2459640/The Women's Dermatologic Society, sponsored by Glytone, will hold a “Look Before You Leap” Media Day 2013 on January 15, a series of desk-side appointments with the editorial community focusing on the pitfalls, complications, problems, and myths surrounding skin care and dermatology topics. Founded
- Tana Poppino to Be Celtic Complexion Sponsorhttps://practicaldermatology.com/news/20130110-tana_poppino_to_be_celtic_complexion_sponsor/2459641/Florida-based skin care company Celtic Complexion announced a sponsorship agreement with professional rodeo barrel racer Tana Poppino. Ms. Poppino, who lives in Big Cabin, OK, is a full-time contestant on the professional rodeo circuit. S
- DemaSculpt Offers Free Sampleshttps://practicaldermatology.com/news/20130110-demasculpt_offers_free_samples/2459642/To celebrate the launch of their post-injection, anti-bruising cream PostFill, DemaSculpt will include a free sample (a $17.95 value) with each DemaSculpt order received before January 31. In addition, all orders over $198 ship free in Januar
- Jan Marini Skin Research Launches Regeneration Boosterhttps://practicaldermatology.com/news/20130110-jan_marini_skin_research_launches_regeneration_booster/2459643/Jan Marini Skin Research released its all-new Regeneration Booster. Cycloastragenol, TGF Beta-1, multiple beneficial growth factors, and four advanced anti-aging peptides are combined with coenzyme Q10 and additional antioxidants to reduce the a
- Winter Rosacea Treatmentshttps://practicaldermatology.com/news/20130108-winter_rosacea_treatments/2459646/Winter weather and the associated heating systems can easily aggravate sensitive and rosacea-prone skin. With Rosacea Awareness Month coming up this April, the following products can help sooth and calm the redness and irritation associated with rosacea.
- Layoffs at Medicis top 300, with 117 staffers chosen to stayhttps://practicaldermatology.com/news/20130104-layoffs_at_medicis_top_300_with_117_staffers_chosen_to_stay/2459648/The layoff toll at Medicis Pharmaceutical has topped 300, the Phoenix Business Journal reports. Valeant Pharmaceuticals ($VRX), which wrapped up its buyout of the Arizona-based skin drug company last week, has cut 319 staffers--and kept 117--as it integrates Medicis into its own dermatology operatio
- Promius Pharma, LLC Increases Sales Force by 50 Percenthttps://practicaldermatology.com/news/20130102-promius_pharma_llc_increases_sales_force_by_50_percent/2459650/Promius Pharma, LLC is expanding its sales force to 60 from 40. Promius Pharma, which markets clinical prescription products to the US dermatology community, is in growth mode according to Rob D'Urso, head of sales and marketing for the company. “Promius Pharma is gearing up for significant growth
- Results Released from Phase 2 Trial of IMO-3100 in Plaque Psoriasishttps://practicaldermatology.com/news/20121219-results_released_from_phase_2_trial_of_imo-3100_in_plaque_psoriasis/2459655/In a recent study, Idera Pharmaceuticals reported that 48 percent of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in
- Murad Names Suzanne Dawson Chief Marketing Officerhttps://practicaldermatology.com/news/20121213-murad_names_suzanne_dawson_chief_marketing_officer/2459658/Murad Inc. named Suzanne Dawson Chief Marketing Officer, overseeing all global marketing including brand development, advertising, public relations, creative, and education, for products, services, and new market opportunities. Dawson comes to Murad
- Court: Off-label Drug Promotion Is Protected Speechhttps://practicaldermatology.com/news/20121204-court_off-label_drug_promotion_is_protected_speech/2459665/The 2nd US Circuit Court of Appeals in New York voted 2-1 to overturn a pharmaceutical salesman's conviction for off-label drug marketing, citing violations against his free speech rights under the First Amendment. The ruling could threaten FDA rules that prevent the marketing of treatments for uses